Abstract S41 Table
VariablePred arm n  =  31Placebo arm n  =  29P Value Pred vs placebo
Group characteristics
    FEV1 (% predicted)98 (92 to 104)91 (85 to 97)0.26
    Aspirin sensitivityn  =  15n  =  150.89
    Asthman  =  11n  =  110.23
    Total IgE (kU/l)*93.6 (57.6 to 151.9)101.7 (56.4 to 183.6)0.43
    Methacholine PC20 (mg/ml)*1.2 (0.5 to 3.1)1.6 (0.9 to 2.8)0.65
Mini RQLQ (units)
    Baseline1.62 (1.23 to 2.01)2.17 (1.51 to 2.83)0.75
    Post tablets0.75 (0.33 to 1.16)†1.73 (1.21 to 2.24)0.001
    Post nasal drops0.75 (0.46 to 1.03)†0.69 (0.45 to 0.94)†0.25
    Post nasal spray0.66 (0.45 to 0.87)†1.08 (0.72 to 1.44)†0.12
PNIF (l/min)
    Baseline111 (95 to 127)111 (79 to 143)0.92
    Post tablets145 (128 to 163)†133 (100 to 166)0.11
    Post nasal drops148 (131 to 165)†160 (126 to 195)†0.75
    Post nasal spray147 (129 to 165)†146 (110 to 183)0.59
Anosmia score (0–100 mm)
    Baseline62.04 (49.01 to 75.06)55.58 (40.90 to 70.26)0.75
    Post tablets32.96 (22.23 to 43.69)†59.50 (47.43 to 71.57)0.001
    Post nasal drops33.69 (22.48 to 44.90)†43.98 (30.88 to 57.08)0.25
    Post nasal spray34.65 (23.79 to 45.52)†47.25 (34.56 to 59.94)0.12
Endoscopy score (0–6)
    Baseline4.7 (4 to 5.5)4.8 (4 to 6)0.66
    Post tablets2.6 (2 to 3)†4.7 (4 to 5)<0.001
    Post nasal drops2.2 (1 to 3.5)†3.2 (3 to 4)†0.002
    Post nasal spray2.8 (2 to 4)†3.3 (2 to 4)†0.04
OUCC* (nmol/mmol)
    Baseline8.07 (6.27 to 10.40)8.70 (7.04 to 10.73)0.93
    Post tablets14.52 (8.95 to 23.55)7.62 (6.39 to 9.09)0.03
    Post nasal drops7.74 (5.79 to 10.37)7.48 (5.98 to 9.35)0.68
    Post nasal spray8.51 (6.36 to 11.35)8.14 (6.38 to 10.42)0.83

  • *Indicates geometric mean and 95% CI. †Indicates statistically significant change from baseline values (p<0.05). RQLQ, rhinoconjunctivitis quality of life questionnaire; PNIF, peak nasal inspiratory flow rate; Pred, prednisolone 25 mg od for 2 weeks.